Organization
Clinical Immunology, Amgen, Thousand Oaks, United States
1 abstract
Abstract
A RANDOMIZED, SINGLE-BLIND, SINGLE-DOSE, THREE-ARM, PARALLEL GROUP STUDY IN HEALTHY SUBJECTS TO DEMONSTRATE PHARMACOKINETIC EQUIVALENCE OF ABP 501 AND ADALIMUMAB: RESULTS OF COMPARISON WITH ADALIMUMAB (EU) Org: Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, PK and Drug Metabolism, Statistics Division, Clinical Immunology, Amgen, Thousand Oaks, United States,